Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phendimetrazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.41 |
| ▸ | SLC6A3 known ✓ | Q01959 | 5/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 2/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phendimetrazine SCHEMBL29353044 | 1.00 | HTR1A (0.75) | HTR1AKDM4EBLMALOX15SLC6A2 | |
| Phendimetrazine SCHEMBL15064941 | 1.00 | HTR1A (0.75) | HTR1AKDM4EBLMALOX15SLC6A2 | |
| Phendimetrazine SCHEMBL160376 | 1.00 | HTR1A (0.75) | HTR1AKDM4EBLMALOX15SLC6A2 | |
| Phendimetrazine SCHEMBL160375 | 1.00 | HTR1A (0.75) | HTR1AKDM4EBLMALOX15SLC6A2 | |
| Phendimetrazine SCHEMBL10613088 | 0.99 | HTR1A (0.73) | HTR1AKDM4EBLMALOX15SLC6A2 | |
| Phendimetrazine SCHEMBL21603017 | 0.88 | HTR1A (0.57) | HTR1AKDM4EBLMALOX15CYP2D6 | |
| Phendimetrazine SCHEMBL15064942 | 0.87 | HTR1A (1.00) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL49481 | 0.87 | HTR1A (1.00) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL344020 | 0.87 | HTR1A (1.00) | HTR1ASLC6A2SLC6A3HTR2BADRA1A | |
| Phendimetrazine SCHEMBL598950 | 0.87 | HTR1A (1.00) | HTR1ASLC6A2SLC6A3HTR2BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115240227-A | Oral panoramic film permanent tooth segmentation and tooth position identification method based on deep learning | 成都仁恒美光科技有限公司 | 2022-10-25 | — | — | CN | claimed |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2025-05-29 | — | — | US | disclosed |
| US-20250049881-A1 | FORMULATIONS OF GUANYLATE CYCLSE C AGONISTS AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. | 2025-02-13 | — | — | US | disclosed |
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2024-11-19 | — | — | US | disclosed |
| EP-4424697-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | Bausch Health Ireland Limited (IE) | 2024-09-04 | — | — | EP | disclosed |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2024-08-29 | — | — | US | disclosed |
| EP-3004138-B1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LTD (IE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4309673-A2 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Bausch Health Ireland Limited (IE) | 2024-01-24 | — | — | EP | disclosed |
| US-20240002440-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2024-01-04 | — | — | US | disclosed |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2023-10-26 | — | — | US | disclosed |
| EP-3708179-B1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | BAUSCH HEALTH IRELAND LTD (IE) | 2023-10-04 | — | — | EP | disclosed |
| CN-109791625-B | Facial recognition using artificial neural networks | NTECH实验室有限责任公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-115240227-A | Oral panoramic film permanent tooth segmentation and tooth position identification method based on deep learning | 成都仁恒美光科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-112348167-B | Knowledge distillation-based ore sorting method and computer-readable storage medium | 华东交通大学 | 2022-10-11 | — | — | CN | disclosed |
| CN-112749626-B | DSP platform-oriented rapid face detection and recognition method | 同济大学 | 2022-09-13 | — | — | CN | disclosed |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | SLC6A2 1820/4885SLC6A3 1488/4885HTR1A 649/4885 |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | SLC6A2 1820/4885SLC6A3 1488/4885HTR1A 649/4885 |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | SLC6A2 1820/4885SLC6A3 1488/4885HTR1A 649/4885 |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | SLC6A2 1820/4885SLC6A3 1488/4885HTR1A 649/4885 |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | SLC6A2 1820/4885SLC6A3 1488/4885HTR1A 649/4885 |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | SLC6A2 1820/4885SLC6A3 1488/4885HTR1A 649/4885 |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | SLC6A2 1820/4885SLC6A3 1488/4885HTR1A 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.